658 results on '"Gladman, Dafna D"'
Search Results
2. Psoriatic Arthritis and COVID-19: Patient Perspectives in a Large Psoriatic Arthritis Cohort.
3. Proceedings of the GRAPPA 2022 Executive Retreat.
4. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting.
5. Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group.
6. Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis.
7. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting.
8. Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network.
9. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network.
10. Evaluating the threshold score for classification of systemic lupus erythematosus using the EULAR/ACR criteria.
11. Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors.
12. Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
13. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting
14. Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group
15. Proceedings of the GRAPPA 2022 Executive Retreat
16. Effectiveness of Disease-Modifying Antirheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort.
17. Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial.
18. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
19. Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group.
20. Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics.
21. Canadian Rheumatologists' Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis.
22. Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis.
23. Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus.
24. Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
25. Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus.
26. Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis.
27. Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.
28. Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis.
29. Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015.
30. Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?
31. Predictive Utility of Cardiovascular Risk Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review.
32. Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.
33. Liver Abnormalities in Patients with Psoriatic Arthritis.
34. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
35. Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity.
36. Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus.
37. Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story.
38. Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis
39. Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis
40. Isolated Neutropenia in Systemic Lupus Erythematosus.
41. Sex Effect in Psoriatic Arthritis.
42. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
43. Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.
44. Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.
45. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
46. Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?
47. Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set.
48. Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?
49. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus.
50. Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.